The anti-SLAMF7 elotuzumab enhances ADCC activity with Th1-like γδT cells towards osteoclasts and myeloma cells

The anti-SLAMF7 elotuzumab enhances ADCC activity with Th1-like γδT cells towards osteoclasts and myeloma cells

Bibliographic Details
Main Authors:	Hirofumi Tenshin, Takeshi Harada, Yusuke Inoue, Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Kotaro Tanimoto, So Shimizu, Yoshiki Higa, Masahiro Oura, Kimiko Sogabe, Tomoyo Hara, Tomoko Maruhashi, Itsuro Endo, Toshio Matsumoto, Eiji Tanaka, Masahiro Abe
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	Bone Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352187221001571

Similar Items

TAK1 inhibition effectively suppresses NLRP3 inflammasome-mediated inflammation and osteoclastic bone resorption in rheumatoid arthritis
by: Hirofumi Tenshin, et al.
Published: (2020-10-01)

Mechanical unloading enhances bone destruction and tumor expansion in multiple myeloma: Critical roles of osteocytic RANKL induction
by: Kotaro Tanimoto, et al.
Published: (2020-10-01)

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
by: Friend R, et al.
Published: (2017-03-01)

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
by: Kerry S. Campbell, et al.
Published: (2018-11-01)

ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING
by: Masafumi Taniwaki, et al.
Published: (2018-02-01)

γδT cells are ADCC effectors in elite HIV controllers
by: Armstrong Cheryl, et al.
Published: (2010-05-01)

The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat
by: Mohannad Ashtar, et al.
Published: (2020-04-01)

The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms
by: Tatiana Pazina, et al.
Published: (2017-09-01)

Myeloma–Bone Interaction: A Vicious Cycle via TAK1–PIM2 Signaling
by: Takeshi Harada, et al.
Published: (2021-09-01)

Persistent Activation of Calcium‐Sensing Receptor Suppresses Bone Turnover, Increases Microcracks, and Decreases Bone Strength
by: Bingzi Dong, et al.
Published: (2019-07-01)

Elotuzumab for the treatment of multiple myeloma
by: Yucai Wang, et al.
Published: (2016-07-01)

Negative regulation of humoral immunity due to interplay between the SLAMF1, SLAMF5, and SLAMF6 receptors
by: Ninghai eWang, et al.
Published: (2015-04-01)

Role and Mechanism of SLAMF7-SLAMF7 Signaling Pathway in Tumor Progression
by: WANG Yuanyuan, et al.
Published: (2020-04-01)

CRISPR-Mediated Triple Knockout of SLAMF1, SLAMF5 and SLAMF6 Supports Positive Signaling Roles in NKT Cell Development.
by: Bonnie Huang, et al.
Published: (2016-01-01)

Elotuzumab for Treatment of Multiple Myeloma (Literature Review)
by: OM Votyakova
Published: (2016-10-01)

Profile of elotuzumab and its potential in the treatment of multiple myeloma
by: Liu YC, et al.
Published: (2014-06-01)

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
by: Weisel K
Published: (2016-10-01)

Responses to microbial challenges by SLAMF receptors
by: Boaz Job Van Driel, et al.
Published: (2016-01-01)

Migration of myeloid cells during inflammation is differentially regulated by the cell surface receptors Slamf1 and Slamf8.
by: Guoxing Wang, et al.
Published: (2015-01-01)

Activation status of γδ T cells dictates their effect on osteoclast generation and bone resorption
by: Swati P. Phalke, et al.
Published: (2015-12-01)

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab
by: Chen WC, et al.
Published: (2017-07-01)

CRISPR-Mediated Slamf1Δ/Δ Slamf5Δ/Δ Slamf6Δ/Δ Triple Gene Disruption Reveals NKT Cell Defects but Not T Follicular Helper Cell Defects.
by: Joyce K Hu, et al.
Published: (2016-01-01)

SLAMF6 clustering is required to augment T cell activation.
by: Matthew A Dragovich, et al.
Published: (2019-01-01)

Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide
by: Wang H, et al.
Published: (2021-04-01)

SLAMF7 engagement superactivates macrophages in acute and chronic inflammation
by: Blazar, P., et al.
Published: (2022)

The Yin and Yang of ADCC-Mediating Antibodies
by: Marjorie Robert-Guroff
Published: (2016-01-01)

Olopatadine Inhibits Exocytosis in Rat Peritoneal Mast Cells by Counteracting Membrane Surface Deformation
by: Asuka Baba, et al.
Published: (2015-01-01)

Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective
by: Trudel S, et al.
Published: (2019-07-01)

The importance of retaining physical functions to prevent skeletal-related events in multiple myeloma patients with bone disease
by: Hirokazu Miki, et al.
Published: (2021-04-01)

Association of circulating SLAMF7+Tfh1 cells with IgG4 levels in patients with IgG4-related disease
by: Kazuhiko Higashioka, et al.
Published: (2020-06-01)

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
by: Liping Liu, et al.
Published: (2016-07-01)

Development of a Macrophage-Based ADCC Assay
by: Melissa B. Uccellini, et al.
Published: (2021-06-01)

Sonic Hedgehog Is a Determinant of γδ T-Cell Differentiation in the Thymus
by: Konstantinos Mengrelis, et al.
Published: (2019-07-01)

Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis
by: Yuan He, et al.
Published: (2019-02-01)

SLAMF1 Promotes Methotrexate Resistance via Activating Autophagy in Choriocarcinoma Cells
by: Shi D, et al.
Published: (2020-12-01)

SAP-independent and -dependent regulation of innate T cell development involving SLAMF receptors
by: Jaime eDe Calisto, et al.
Published: (2014-04-01)

Pathogenesis and treatment of multiple myeloma bone disease
by: Masahiro Hiasa, et al.
Published: (2021-11-01)

Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors.
by: Takeshi Harada, et al.
Published: (2013-01-01)

A novel assay for analysis of the regulation of the function of human osteoclasts
by: Chambers Timothy J, et al.
Published: (2006-11-01)

SLAMF1 contributes to cell survival through the AKT signaling pathway in Farage cells.
by: Heejei Yoon, et al.
Published: (2020-01-01)